Document is current
Any future updates will be listed below
-
Authors
Pellesi, Lanfranco https://orcid.org/0000-0003-4137-5039
Do, Thien Phu https://orcid.org/0009-0002-3662-5582
Ernst, Martin Thomsen https://orcid.org/0000-0001-9003-3823
Hallas, Jesper https://orcid.org/0000-0002-8097-8708
Pottegård, Anton https://orcid.org/0000-0001-9314-5679
- License Information
-
More Information
Article History
Received: 27 February 2025
Accepted: 7 April 2025
First Online: 18 April 2025
Declarations
:
: L.P. was formerly employed by Lundbeck. T.P.D. has received personal fees from Teva that are unrelated to this manuscript. J.H. and A.P. reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, Pfizer and LEO Pharma (all regulator-mandated Phase IV studies), and an unrestricted research grant from Novo Nordisk, all with funds paid to the institution where they were employed (no personal fees) and with no relation to the work reported in this paper. M.T.E. reports no conflict of interests.
